




GOOD PRACTICE GUIDE:

Technology Transfer

Third Edition



Product and Process Knowledge
Analytical Procedure
Drug Substance
Drug Product



GOOD PRACTICE GUIDE:

Technology Transfer

Third Edition

Disclaimer:

This *ISPE Good Practice Guide: Technology Transfer Guide (Third Edition)* provides information for technology transfers between two parties for any applicable transfers in the product lifecycle. This Guide is solely created and owned by ISPE. It is not a regulation, standard or regulatory guideline document. ISPE cannot ensure and does not warrant that a system managed in accordance with this Guide will be acceptable to regulatory authorities. Further, this Guide does not replace the need for hiring professional engineers or technicians.

Limitation of Liability

In no event shall ISPE or any of its affiliates, or the officers, directors, employees, members, or agents of each of them, or the authors, be liable for any damages of any kind, including without limitation any special, incidental, indirect, or consequential damages, whether or not advised of the possibility of such damages, and on any theory of liability whatsoever, arising out of or in connection with the use of this information.

© Copyright ISPE 2018. All rights reserved.

All rights reserved. No part of this document may be reproduced or copied in any form or by any means – graphic, electronic, or mechanical, including photocopying, taping, or information storage and retrieval systems – without written permission of ISPE.

All trademarks used are acknowledged.

ISBN 978-1-946964-15-1

Preface

Transfer of manufacturing processes and analytical procedures between facilities or laboratories is a necessary part of pharmaceutical development and commercialization. Technology transfers take the outputs of process or method development activities and transfer the knowledge to a different location where a process or analytical procedure will be operated. This third edition of the ISPE Good Practice Guide: Technology Transfer was developed by an international team of authors from across the industry. This Guide presents a general approach and good practices for effective technology transfer with redacted case studies as examples. The intent is for the reader to utilize Chapters 1, 2, and 3 as a foundation and the subsequent chapters as applicable. The reader is encouraged to utilize the various lists, tables, figures, and templates for illustrative purposes.

Acknowledgements

The Guide was produced by a Core Team of contributing authors led by Bruce Davis (Global Consulting, United Kingdom) and John Herberger (Amgen Inc., USA).

Core Team

The following individuals took lead roles in the preparation of this Guide:

Suzanne Aldington	Lonza	United Kingdom
Mervin H. (Vinny) Browning III, MS	Amgen Inc.	USA
Jose A. Caraballo	Bayer U.S.	USA
Mike Cohen	Pfizer Inc.	USA
Beth Haas	CAI	USA
Corinne Kikegawa	Amgen Inc.	USA
Maurice Parlane	New Wayz Consulting Ltd./CBE Pty Ltd.	New Zealand
Ruchi Thombre	Pfizer Inc.	USA
Noreen Troccoli	Sanofi	USA
Maria Vazquez-Rey	Lonza Biologics Porriño	Spain
Nick Vrolijk	Celldex Therapeutics Inc.	USA

Special Thanks

The Team would like to thank Timothy Watson (Pfizer Inc., USA) for his ongoing support during development of this Guide. The Team would also like to thank ISPE for technical writing and editing support by Nina Wang (ISPE Guidance Documents Technical Writer/Editor) and production/process support by Lynda Goldbach (ISPE Guidance Documents Manager) and Konyika Nealy (ISPE Senior Director, Guidance Documents and Knowledge Networks).

The Team Leads would like to express their grateful thanks to the many individuals and from around the world, too numerous to list here, who reviewed and provided comments during the preparation of this Guide. The feedback was highly valuable and made a significant contribution to the quality of the third edition.

Company affiliations are as of the final draft of the Guide.



600 N. Westshore Blvd., Suite 900, Tampa, Florida 33609 USA
Tel: +1-813-960-2105, Fax: +1-813-264-2816

www.ISPE.org

Table of Contents

1	Introduction	7
1.1	Background and Purpose	7
1.2	Rationale for this Third Edition	8
1.3	Scope	15
1.4	Key Terms	17
2	Technology Transfer - Planning Considerations and Success Criteria.....	21
2.1	Introduction	21
2.2	Technology Transfer Planning Considerations.....	21
2.3	Technology Transfer Success Criteria	27
3	Technology Transfer Project Phases	31
3.1	Form Transfer Team and Develop Charter	31
3.2	Consolidate Knowledge for Transfer and Develop Technology Transfer Proposal	35
3.3	Identify Risks, Conduct Risk Assessments, and Develop Technology Transfer Plan	37
3.4	Operational Readiness	44
3.5	Process (Procedure) Qualification	47
3.6	Finalize Transfer and Perform Review.....	48
4	Technology Transfer of Analytical Methods.....	53
4.1	Introduction	53
4.2	Technology Transfer Process.....	54
4.3	Points to Consider.....	64
4.4	Additional Sources of Information	65
5	Technology Transfer of Drug Substance.....	67
5.1	Introduction	67
5.2	Technology Transfer Process.....	67
5.3	Points to Consider.....	79
5.4	Example Gap Analyses for Small Molecule and Large Molecule Processes.....	79
6	Technology Transfer of Drug Product.....	83
6.1	Introduction	83
6.2	Technology Transfer Process.....	83
7	Quality Aspects of Technology Transfer.....	89
7.1	Introduction	89
7.2	Quality Representation on the Technology Transfer Team	89
7.3	Quality by Design and Control Strategy.....	89
7.4	Quality Risk Management.....	90
7.5	Analytical Comparability/Similarity and Stability Strategy	91
7.6	Process Validation/Process Performance Qualification Strategy.....	92
7.7	Change Management	93
7.8	Execution	94

8	Appendix 1 – Checklist of Information/Documents for Large and Small Molecule Technology Transfer	95
9	Appendix 2 – Case Studies: Biologics	97
9.1	Summary	97
9.2	Main Challenges	97
9.3	Overview of Technology Transfer Phases	98
9.4	Risk Management	100
9.5	Technology Transfer Case Studies	101
9.6	Conclusions/Lessons Learned	111
10	Appendix 3 – Case Studies: Small Molecule	113
10.1	Summary	113
10.2	Main Challenges	113
10.3	Technology Transfer Process	113
10.4	Technology Transfer Case Studies	115
11	Appendix 4 – Engineering Considerations for Technology Transfer	123
11.1	Introduction	123
11.2	Examples	126
11.3	Lessons Learned	128
12	Appendix 5 – Example of a Failure Mode and Effect Analysis (FMEA) for a Non-Sterile Drug Product	135
13	Appendix 6 – Example of Information that May be Included in Technology Transfer Report	137
14	Appendix 7 – References	141
15	Appendix 8 – Glossary	145
15.1	Acronyms and Abbreviations	145
15.2	Definitions	146

1 Introduction

1.1 Background and Purpose

Transfer of manufacturing processes and analytical procedures between facilities or laboratories is a necessary part of pharmaceutical development and commercialization. Technology transfers may utilize the outputs of process and method development activities and/or documentation of established processes and methods. Knowledge of the product and the manufacturing process is the basis for transfer to a different location (which could be a different site, country, or facility on the same site) where a process or analytical procedure will be operated.

This Guide focuses on how technology transfer can be achieved.

Technology transfer is defined in ICH Q10 [1] paragraph 3.1.2 as follows:

“The goal of technology transfer activities is to transfer product and process knowledge between development and manufacturing, and within or between manufacturing sites to achieve product realisation. This knowledge forms the basis for the manufacturing process, control strategy, process validation approach and ongoing continual improvement.”

Technology transfer projects may take place at various points during the product lifecycle. Successful transfers depend on robust project management processes combined with appropriate product and process understanding. They require partnership, cooperation, and coordination between the sending and receiving units to ensure successful and efficient completion, such that the receiving unit can manufacture, test, and release a safe, efficacious, and quality product comparable to that of the sending unit.

Technology transfer projects are dependent on the development and characterization of robust processes that allow consistent and predictable operation of these processes. Similarly, development of robust analytical methods enables timely transfer of methods. These are particularly important aspects; if processes are not well developed and sources of variation are not well known, e.g., due to incomplete or inadequate process/product knowledge, then technology transfer will not be robust.

This Guide has been designed to present industry good practices for successful and efficient execution of technology transfer projects and to achieve a balance between risk management and cost effectiveness while aligning with applicable regulatory expectations, as described in ICH Q7, Q8(R2), Q9, Q10, and Q11 [2, 3, 4, 1, 5] and other regulatory documents. It covers the principles of technology transfer and provides tools for its practical application.

The impetus for technology transfer varies and may be based on several factors, for example:

Progression in a product development lifecycle, from development through scale-up to commercialization
The need for additional manufacturing capacity driven by increased demand or risk mitigation

- The need to streamline capacity when volumes fall, e.g., at patent expiry, when products change commercial status from novel to generic, etc.
- Strategic requirements to relocate business units, e.g., regional economic advantages, regional requirements for local manufacture, global expansion in different regions of the world, etc.
- Identification and qualification of local analytical facilities for testing of intermediates and finished products to meet regional regulatory requirements
- Dual sourcing strategies to mitigate demand variability or to reduce sourcing risks from manufacturing sites